Soleno Therapeutics (SLNO, Financial) experienced a notable stock price increase of 9.11% following positive developments in its regulatory process. This performance far exceeded that of the S&P 500 index, which saw gains of less than 1%. The catalyst behind this surge is the announcement that the FDA will not require an advisory committee meeting for its New Drug Application (NDA) for diazoxide choline (DCCR) tablets, which are designed to treat Prader-Willi Syndrome. This move suggests a potentially smoot ...